injectable filler

Merz Pharmaceuticals, LLC, today announced that data from studies evaluating the dosing and adverse event profiles of Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, in the treatment of blepharospasm (eyelid spasms) will be presented at the 115th Annual Meeting of the American Association of Ophthalmology (AAO) in Orlando, Fla. These data include an extension of the Phase III, randomized, placebo-controlled, double-blind trial that assessed the safety and efficacy of XEOMIN in blepharospasm, which was recently published in the July 2011 issue of Movement Disorders , the official journal of the Movement Disorders Society.

The Food and Drug Administration (FDA) has approved Xeomin (incobotulinumtoxinA, Merz Aesthetics) for temporary improvement of moderate to severe glabellar lines, Medscape Today reports. According to a Merz statement, the approval is based on the results of two multicenter U.S.

An injectable cosmetic filler that smooths out facial wrinkles has been suspended from use after it was found to cause painful redness, bruising and swelling in some patients.    Novabel is marketed as “the gentle, powerful, versatile dermal shaper” by its manufacturer, Merz.

Merz Aesthetics today announced it is now shipping Asclera™ (polidocanol) Injection sclerotherapy treatment to doctors’ offices throughout the U.S.  Previously only available in Europe, Asclera™ was recently approved by the U.S. Food and Drug Administration (FDA). In a study published in the June issue of Phlebology, leading experts conclude that polidocanol is a highly effective sclerotherapy treatment.